
Sign up to save your podcasts
Or


In this interview, Stephen J. Nicholls and Sotirios Tsimikas discuss AKCEA: Safety and Efficacy of AKCEA-APO(a)-to Lower Lipoprotein(a) Levels in Patients with Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial.
By American College of Cardiology3.8
5858 ratings
In this interview, Stephen J. Nicholls and Sotirios Tsimikas discuss AKCEA: Safety and Efficacy of AKCEA-APO(a)-to Lower Lipoprotein(a) Levels in Patients with Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial.

518 Listeners

321 Listeners

504 Listeners

167 Listeners

906 Listeners

21 Listeners

31 Listeners

298 Listeners

3,374 Listeners

138 Listeners

1,150 Listeners

39 Listeners

367 Listeners

437 Listeners

32 Listeners